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and oligonephropathy and ultimately con-
tribute to developmental programming for 
late hypertension ( Figure 1 ). 3 
 Th is work by Bacchetta  et al. 4 empha-
sizes the potentially pivotal role of nutri-
tion in the earliest days of extrauterine life. 
Although neonatal intensive care units are 
known to be bastions of attention to detail, 
the study from Japan by Sakurai  et al. 
shows that despite the institution of 
parenteral nutrition and trophic feeding 
as standard nutritional management strat-
egies for very-low-birth-weight infants, 
EUGR continues to be a central problem 
for preterm low-birth-weight infants  ≤ 32 
weeks ’ gestational age. The longer the 
period of time before complete enteral 
feeding was achieved, the greater was the 
risk of EUGR for weight and head cir-
cumference. 9 To maximize the potential 
for nephrogenesis, continued attention 
needs to be devoted in neonatal intensive 
care units to maintaining adequate caloric 
and protein intake in the earliest of post-
natal days. Th is is complicated by confl ict-
ing reports that low-nutrient conditions 
following birth have a positive eff ect on 
adult insulin receptivity. 9 Therefore, a 
dilemma persists between pursuing 
aggressive and pursuing non-aggressive 
degrees of nutrition, with the long-term 
eff ects of aggressive nutrition requiring 
further study. What new strategies can be 
developed to capitalize on the window of 
opportunity of postnatal nephrogenesis? 
 Th e fi ndings of Bacchetta  et al. 4 are pro-
vocative and should stimulate new work 
in the fi eld, as studies with larger numbers 
of premature children in a racially diverse 
ethnic population are needed to validate 
their fi ndings. Th e data would be further 
supported by the determination of GFR 
by inulin clearance in normal-birth-
weight full-term controls. With a larger 
number of children with EUGR, the like-
lihood of a diff erence between males and 
females can also be assessed to determine 
whether female gender aff ords some pro-
tection against the detrimental eff ects of 
postnatal  protein restriction. 
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 Diabetes is recognized as the most com-
mon cause of chronic kidney disease 
worldwide, with the majority of incident 
cases of end-stage renal disease in the 
United States attributed to diabetic neph-
ropathy. The pathogenesis of diabetic 
nephropathy is complex but is largely 
characterized by glomerular fibrosis. 
The predominant histologic lesion is 
glomerular enlargement due to deposition 
of interstitial collagens and a variety of 
other  ‘ scar matrix ’ proteins, which accu-
mulate within the thickened glomerular 
basement membranes in a mesangial pat-
tern and / or as Kimmelstiel-Wilson nod-
ules in the glomerular periphery. 
Interstitial fi brosis, which is composed of 
similar extracellular matrix proteins 
between tubules, is also an important pre-
dictor of diabetic nephro pathy outcomes. 
Mainstay therapies such as glucose and 
blood pressure control can slow diabetic 
nephropathy progression, and some of 
these regimens may be particularly eff ec-
tive because the pharmacologic agents 
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 Diabetic nephropathy is characterized by enhanced glomerular and 
tubulointerstitial deposition of extracellular matrix proteins, which are 
bound together by tissue transglutaminase (TG2). Huang  et al. 
demonstrate that infusion of a novel TG2 inhibitor in diabetic rats 
prevented renal scarring and albuminuria and preserved glomerular 
filtration rate. These studies confirm the role of TG2 in the pathogenesis 
of diabetic nephropathy and add to an emerging literature that 
demonstrates that TG2 is an attractive therapeutic target for sclerosing 
kidney diseases. 
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have the additive eff ect of interrupting 
scar matrix protein deposition. However, 
specifi c antifi brotic agents have not been 
convincingly shown to be benefi cial for 
diabetic nephropathy, in part because the 
mechanism by which multiple extracel-
lular matrix proteins become intertwined 
within glomerular and interstitial scars is 
not well understood. 
 Transglutaminases (TGs) are a family of 
eight enzymes (factor XIII and TG1 – TG7) 
that catalyze formation of covalent 
bonds between free   -amino groups (usu-
ally from a lysine residue) and a   -
 carboxyamine group from a glutamine on 
adjacent peptides or proteins ( Figure 1 ). 
Tissue transglutaminase (tTG, or TG2) is 
an 80-kDa protein that resides mainly in 
the cytosol and has several enzymatic 
functions, including transamidase (cross-
linking), deaminase, isopeptidase, GTPase, 
protein kinase, and protein disulfi de iso-
merase activities. 1 Despite lacking a signal 
peptide sequence, TG2 is unique among 
family members because a small fraction 
of total cellular TG2 is secreted. Th e abun-
dance of extracellular TG2 is enhanced in 
the context of cellular injury. In the envi-
ronment of relatively high extracellular 
Ca 2  +   concentration, TG2 acts as a bio-
logical glue by binding and covalently 
cross-linking extracellular matrix proteins, 
such as collagens and fi bronectin, to form 
large heteromeric complexes ( Figure 1 ), 
which are resistant to proteolysis. 2 Th is 
cross-linking function of TGs has been 
exploited in the food industry to provide 
texture to pasta and milk products, and as 
 ‘ meat glue ’ to bind pieces of meat to form 
sausages, hot dogs, and steaks. 
 TG2 has been associated with multiple 
physiologic functions, many of which are 
relevant to glomerular diseases, including 
cell adhesion and migration, apoptosis, 
wound healing, insulin secretion, and 
transforming growth factor-  (TGF-  ) 
activation. 1,2  TGM2   −  /  −   mice have no 
overt phenotype, perhaps because of com-
pensation by other TG isoforms, whereas 
mice with  TGM2 transgene overexpres-
sion under the control of a cardiac-specifi c 
promoter developed cardiac fibrosis 
(reviewed by Griffi  n  et al. 2 ). In humans, 
TG2 has been most notably implicated 
in the pathogenesis of celiac disease, 
wherein IgA and IgG autoantibodies are 
generated against TG2 cross-linked to the 
gliadin fraction of gluten. 3 TG2 has also 
been associated with neurologic disorders, 
such as Huntington ’ s, Parkinson ’ s, and 
 Alzheimer ’ s diseases, as well as with car-
cinogenesis and fi brosis of the liver, lung, 
heart, and kidney. 
 Now, the University of Sheffi  eld group 
(Huang  et al. , 4 this issue) extends its ongoing 
investigation of the role of TG2 in the 
pathogenesis of diabetic glomerulosclero-
sis and interstitial fi brosis by demonstrat-
ing that pharmacologic inhibition of TG2 
ameliorated pathologic lesions and renal 
dysfunction in a rat model of diabetic 
nephropathy. The model used was the 
streptozotocin-induced diabetic rat, which 
underwent uninephrectomy to accelerate 
disease progression. Osmotic minipumps 
containing the irreversible TG2 inhibitor 
 N -benzyloxycarbonyl- L -phenylalanyl-6-
dimethylsulfonium-5-oxo- L -norleucine 
(NTU281) were inserted into the renal 
parenchyma; this was followed by experi-
ments demonstrating uniform distribution 
of NTU281 in a control kidney. Experi-
mental and control rats were examined for 
renal TG activity, pathology, and function 
aft er 1, 4, and 8 months of diabetes. Curi-
ously, kidney TG activity was increased 
three- to fourfold in the untreated diabetic, 
uninephrectomized rats at 1 and 8 months 
but not at 4 months. Nevertheless, this 
does not diminish the impressive main 
findings, that NTU281 infusion nearly 
normalized serum creatinine and albu-
minuria, as well as glomerular and tubu-
lointerstitial scarring at 8 months. 
 Although these results are very encour-
aging, they should be viewed with caution 
before NTU281 can be realistically 
 considered as a therapeutic agent for dia-
betic nephropathy. First, there is the 
generic concern that NTU281-loaded 
osmotic minipumps were inserted directly 
into the renal parenchyma and before the 
onset of diabetes. This is an initial and 
obligatory proof-of-principle approach, 
although it is obviously not applicable to 
human diabetic nephropathy, which is 
routinely not recognized until many years 
after diabetes is diagnosed. With the 
advent of biomarker and susceptibility-
gene discovery, one could envision that 
prophylactic therapy for at-risk diabetic 
patients might one day be realistic. Until 
such tools become  available, a rational next 
step would be to determine whether 
NTU281 might have an eff ect in animals 
with established diabetes or diabetic neph-
ropathy. Second, scant information is pro-
vided about the specifi city of NTU281 for 
TG2, other than that the compound binds 
the active site of TG2 and is exclusively 
eff ective against extracellular TGs (factor 
XIII and TG2). Even if NTU281 is specifi c 
 Figure 1  |  Cross-linking of extracellular matrix proteins by tissue transglutaminase-
regulated transamidation. ( a ) Secreted tissue transglutaminase (TG2), which is stabilized by 
extracellular calcium, forms a thioester bond between a cysteine (Cys 277 ) within its active site and 
an extracellular matrix (ECM) glutamine (Gln) residue on its substrate. Both substrate – TG2 binding 
and TG2 activity are enhanced by calcium and inhibited by guanosine triphosphate (GTP). ( b ) The 
TG2 – substrate intermediate then interacts with another ECM molecule, and TG2 catalyzes an acyl 
transfer reaction to form an isopeptide linkage between Gln and lysine (Lys) residues on adjacent 
ECM proteins ( c ). The net effect of enhanced TG2 activity is that multiple ECM proteins become 
glued together to form sclerotic scars. 
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for TG2, the possibility of off -target eff ects 
with systemic administration is signifi cant, 
since TG2 is ubiquitously expressed in 
other tissues. Th ird, the TG2-regulated 
pathway that was altered by NTU281 was 
not investigated. Th e implication is that 
NTU281 administration improved dia-
betic nephropathy by inhibiting TG2 
cross-linking of extracellular scar matrix 
proteins, consistent with previous studies 
describing increased TG2 expression and 
transamidase activity in human renal biop-
sies, as well as diabetic and nondiabetic rat 
models of chronic renal disease. 5 – 7 Inter-
estingly, NTU281 treatment also inhibited 
whole-kidney type III and IV collagen 
mRNA expression, suggesting that the 
drug eff ects may be more complex than 
simple post-translational modifi cation of 
TG2 substrates. 
 Because TG2 interacts with over 100 sub-
strates, 1 definitive identification of the 
 specifi c target or targets aff ected by NTU281 
could be a bewildering task. In addition to 
extracellular matrix proteins, another perti-
nent substrate is latent TGF-  -binding pro-
tein-1 (LTBP-1), since TG2-catalyzed 
anchoring of LTBP-1 to extracellular matrix 
facilitates subsequent TGF-  activation, 8 
and TGF-  has been implicated in the 
pathogenesis of diabetic glomerulosclero-
sis. 9 In studies with  TGM2   −  /  −   mice, 
Schweke  et al. recently showed that TGF-  
activity was the major mechanism of 
TG2-dependent interstitial fi brosis in a ure-
teral obstruction model. 10 Improved clarifi -
cation of the relative roles of TG2 in 
cross-linking of extracellular matrix proteins 
versus LTBP-1 anchoring in diabetic neph-
ropathy, as well as the impact of NTU281 on 
these two pathways, would be welcome. 
 So although it would be premature at 
this point to consider NTU281 as a thera-
peutic agent for diabetic nephropathy, the 
use of this novel drug as a tool to interro-
gate the role of TG2 in diabetic nephropa-
thy in rats was appropriate. Th is approach 
is akin to using targeted gene deletion 
strategies in mice to decipher functions of 
specifi c proteins, but it has the advantage 
that streptozotocin administration mimics 
diabetic nephropathy more faithfully in 
rats than in mice. Especially when com-
bined with multiple other publications by 
this group about TGs in kidney disease, 
the paper by Huang  et al. 4 clearly extends 
the body of data implicating TG2 in dia-
betic nephropathy pathogenesis. Th is is a 
particularly exciting avenue to pursue 
because current therapies target pathways 
that are unrelated to post-translational 
extracellular matrix protein modifi cation. 
Th erefore, if eff ective treatments can be 
devised to safely target TG2 in the kidney, 
one could envision that there could be 
additive benefi ts to existing regimens for 
diabetic nephropathy, as well as other scar-
ring renal diseases. 
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